BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1167 related articles for article (PubMed ID: 17316149)

  • 1. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micafungin: a new echinocandin.
    Chandrasekar PH; Sobel JD
    Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinocandins in the management of invasive fungal infections, Part 2.
    Morris MI; Villmann M
    Am J Health Syst Pharm; 2006 Oct; 63(19):1813-20. PubMed ID: 16990627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Echinocandin antifungals: review and update.
    Morrison VA
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):325-42. PubMed ID: 16597212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative evaluation of properties and clinical efficacy of the echinocandins.
    Kim R; Khachikian D; Reboli AC
    Expert Opin Pharmacother; 2007 Jul; 8(10):1479-92. PubMed ID: 17661730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.
    Laverdière M; Lalonde RG; Baril JG; Sheppard DC; Park S; Perlin DS
    J Antimicrob Chemother; 2006 Apr; 57(4):705-8. PubMed ID: 16464893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum differentially alters the antifungal properties of echinocandin drugs.
    Paderu P; Garcia-Effron G; Balashov S; Delmas G; Park S; Perlin DS
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2253-6. PubMed ID: 17420211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anidulafungin: a new echinocandin with a novel profile.
    Vazquez JA
    Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.
    García-Agudo L; García-Martos P; Martos-Cañadas J; Aznar-Marín P; Marín-Casanova P; Rodríguez-Iglesias M
    Rev Esp Quimioter; 2012 Dec; 25(4):256-60. PubMed ID: 23303256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anidulafungin: a novel echinocandin.
    Vazquez JA; Sobel JD
    Clin Infect Dis; 2006 Jul; 43(2):215-22. PubMed ID: 16779750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echinocandin antifungal drugs.
    Denning DW
    Lancet; 2003 Oct; 362(9390):1142-51. PubMed ID: 14550704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to echinocandins in Candida albicans: case report and review.
    Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
    J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.